Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Fly Intel: Top five analyst upgrades » 09:55
07/27/21
07/27
09:55
07/27/21
09:55
AAL

American Airlines

$21.82 /

-0.27 (-1.22%)

, AAP

Advance Auto Parts

$216.60 /

+2.57 (+1.20%)

, TCBI

Texas Capital

$62.90 /

+0.22 (+0.35%)

, WY

Weyerhaeuser

$34.63 /

-0.025 (-0.07%)

, PRLD

Prelude Therapeutics

$34.72 /

+1.52 (+4.58%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Neutral from Negative at Susquehanna and upgraded to Hold from Sell at Berenberg. 2. Advance Auto Parts (AAP) upgraded to Strong Buy from Outperform at Raymond James with analyst Bobby Griffin believing that Advance Auto Parts has the greatest upside potential in the auto part retailer space over the next twelve months. 3. Texas Capital (TCBI) upgraded to Outperform from Neutral at Wedbush with analyst Peter Winter saying he has been "extremely impressed" with new CEO, Rob Holmes, who started in January. 4. Weyerhaeuser (WY) upgraded to Buy from Neutral at BofA with analyst George Staphos seeing potential for a late summer rally in lumber pricing and believes valuation on normalized lumber pricing is attractive given the shares' 14% relative underperformance year-to-date. 5. Prelude Therapeutics (PRLD) upgraded to Buy from Neutral at BofA with analyst Tazeen Ahmad saying the current valuation offers a "particularly attractive buying opportunity." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WY Weyerhaeuser
$34.63 /

-0.025 (-0.07%)

TCBI Texas Capital
$62.90 /

+0.22 (+0.35%)

PRLD Prelude Therapeutics
$34.72 /

+1.52 (+4.58%)

AAP Advance Auto Parts
$216.60 /

+2.57 (+1.20%)

AAL American Airlines
$21.82 /

-0.27 (-1.22%)

AAL American Airlines
$21.82 /

-0.27 (-1.22%)

07/27/21 Susquehanna
American Airlines upgraded to Neutral at Susquehanna
07/27/21 Susquehanna
American Airlines upgraded to Neutral from Negative at Susquehanna
07/27/21 Berenberg
American Airlines upgraded to Hold from Sell at Berenberg
07/23/21 Seaport Global
Seaport Global upgrades 'fixer-upper' American Airlines to Buy
AAP Advance Auto Parts
$216.60 /

+2.57 (+1.20%)

07/27/21 Raymond James
Advance Auto Parts upgraded to Strong Buy from Outperform at Raymond James
07/27/21 Raymond James
Advance Auto Parts upgraded to Strong Buy from Outperform at Raymond James
06/17/21 RBC Capital
Advance Auto Parts at inflection point toward margin expansion, says RBC Capital
06/08/21 Argus
Advance Auto Parts price target raised to $215 from $185 at Argus
TCBI Texas Capital
$62.90 /

+0.22 (+0.35%)

07/27/21 Wedbush
Texas Capital upgraded to Outperform at Wedbush
07/27/21 Wedbush
Texas Capital upgraded to Outperform from Neutral at Wedbush
07/22/21
Fly Intel: Top five analyst upgrades
07/22/21 Piper Sandler
Texas Capital upgraded to Overweight from Neutral at Piper Sandler
WY Weyerhaeuser
$34.63 /

-0.025 (-0.07%)

07/27/21 BofA
Weyerhaeuser upgraded to Buy from Neutral at BofA
07/15/21 Goldman Sachs
Weyerhaeuser initiated with a Buy at Goldman Sachs
05/03/21
Fly Intel: Top five analyst downgrades
05/03/21 Stephens
Stephens downgrades Weyerhaeuser, says shouldn't be mistaken for housing play
PRLD Prelude Therapeutics
$34.72 /

+1.52 (+4.58%)

07/27/21 BofA
Prelude Therapeutics upgraded to Buy from Neutral at BofA
04/26/21 H.C. Wainwright
Prelude Therapeutics initiated with a Buy at H.C. Wainwright
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
WY Weyerhaeuser
$34.63 /

-0.025 (-0.07%)

TCBI Texas Capital
$62.90 /

+0.22 (+0.35%)

PRLD Prelude Therapeutics
$34.72 /

+1.52 (+4.58%)

AAP Advance Auto Parts
$216.60 /

+2.57 (+1.20%)

AAL American Airlines
$21.82 /

-0.27 (-1.22%)

  • 07
    Jan
  • 10
    Nov
  • 25
    Sep
AAL American Airlines
$21.82 /

-0.27 (-1.22%)

AAP Advance Auto Parts
$216.60 /

+2.57 (+1.20%)

AAL American Airlines
$21.82 /

-0.27 (-1.22%)

WY Weyerhaeuser
$34.63 /

-0.025 (-0.07%)

AAL American Airlines
$21.82 /

-0.27 (-1.22%)

Upgrade
Prelude Therapeutics upgraded to Buy from Neutral at BofA » 07:29
07/27/21
07/27
07:29
07/27/21
07:29
PRLD

Prelude Therapeutics

$33.20 /

-0.89 (-2.61%)

BofA analyst Tazeen Ahmad…

BofA analyst Tazeen Ahmad upgraded Prelude Therapeutics to Buy from Neutral with a $60 price target. The current valuation offers a "particularly attractive buying opportunity", the analyst tells investors in a research note. Ahmad adds that the company's PRMT5 approach in oncology is "differentiated with multiple shots on goal" and shows potential to tap into multiple cancer types. The analyst further cites Prelude's catalysts such as additional phase 1 data on '543 in the second half of the year that could represent upside to her current valuation model.

ShowHide Related Items >><<
PRLD Prelude Therapeutics
$33.20 /

-0.89 (-2.61%)

PRLD Prelude Therapeutics
$33.20 /

-0.89 (-2.61%)

04/26/21 H.C. Wainwright
Prelude Therapeutics initiated with a Buy at H.C. Wainwright
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
PRLD Prelude Therapeutics
$33.20 /

-0.89 (-2.61%)

  • 07
    Jan
  • 25
    Sep
Over a week ago
Hot Stocks
Prelude Therapeutics announces appointment of Babler to board of directors » 07:16
07/19/21
07/19
07:16
07/19/21
07:16
PRLD

Prelude Therapeutics

$28.34 /

+0.455 (+1.63%)

Prelude Therapeutics…

Prelude Therapeutics announced the appointment of Martin Babler to its Board of Directors. Babler brings to Prelude over 25 years of pharmaceutical and biotech experience, most recently serving as President and Chief Executive Officer of Principia Biopharma until its acquisition by Sanofi S.A. in October 2020. Babler will serve as a member of the Audit Committee of the Board.

ShowHide Related Items >><<
PRLD Prelude Therapeutics
$28.34 /

+0.455 (+1.63%)

PRLD Prelude Therapeutics
$28.34 /

+0.455 (+1.63%)

04/26/21 H.C. Wainwright
Prelude Therapeutics initiated with a Buy at H.C. Wainwright
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
PRLD Prelude Therapeutics
$28.34 /

+0.455 (+1.63%)

  • 07
    Jan
  • 25
    Sep
Over a month ago
Conference/Events
Prelude Therapeutics management to meet virtually with Truist » 04:55
05/27/21
05/27
04:55
05/27/21
04:55
PRLD

Prelude Therapeutics

$32.96 /

-0.04 (-0.12%)

Virtual Meeting to be…

Virtual Meeting to be held on May 27 hosted by Truist.

ShowHide Related Items >><<
PRLD Prelude Therapeutics
$32.96 /

-0.04 (-0.12%)

PRLD Prelude Therapeutics
$32.96 /

-0.04 (-0.12%)

04/26/21 H.C. Wainwright
Prelude Therapeutics initiated with a Buy at H.C. Wainwright
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
PRLD Prelude Therapeutics
$32.96 /

-0.04 (-0.12%)

  • 07
    Jan
  • 25
    Sep
Conference/Events
Prelude Therapeutics management to meet virtually with Truist » 12:16
05/26/21
05/26
12:16
05/26/21
12:16
PRLD

Prelude Therapeutics

$33.07 /

+0.07 (+0.21%)

Virtual Meeting to be…

Virtual Meeting to be held on May 27 hosted by Truist.

ShowHide Related Items >><<
PRLD Prelude Therapeutics
$33.07 /

+0.07 (+0.21%)

PRLD Prelude Therapeutics
$33.07 /

+0.07 (+0.21%)

04/26/21 H.C. Wainwright
Prelude Therapeutics initiated with a Buy at H.C. Wainwright
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
PRLD Prelude Therapeutics
$33.07 /

+0.07 (+0.21%)

  • 07
    Jan
  • 25
    Sep
Hot Stocks
Prelude Therapeutics expects cash to fund requirements into 2023 » 07:38
05/11/21
05/11
07:38
05/11/21
07:38
PRLD

Prelude Therapeutics

$40.72 /

-0.66 (-1.59%)

Cash and cash equivalents…

Cash and cash equivalents as of March 31, 2021 were $363.0 million. The Company believes that its current cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into 2023.

ShowHide Related Items >><<
PRLD Prelude Therapeutics
$40.72 /

-0.66 (-1.59%)

PRLD Prelude Therapeutics
$40.72 /

-0.66 (-1.59%)

04/26/21 H.C. Wainwright
Prelude Therapeutics initiated with a Buy at H.C. Wainwright
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
PRLD Prelude Therapeutics
$40.72 /

-0.66 (-1.59%)

  • 07
    Jan
  • 25
    Sep
Earnings
Prelude Therapeutics reports Q1 EPS (47c), consensus (42c) » 07:38
05/11/21
05/11
07:38
05/11/21
07:38
PRLD

Prelude Therapeutics

$40.72 /

-0.66 (-1.59%)

"With several novel,…

"With several novel, internally discovered therapeutics now advancing in clinical trials, our pipeline products are off to a strong start in 2021 and we expect this momentum to carry us through multiple key inflection points," said Kris Vaddi, PhD, Chief Executive Officer. "We initiated numerous expansion cohorts for PRT543, our novel PRMT5 inhibitor, in the ongoing Phase 1 trial in patients with advanced solid tumors and hematologic malignancies. We expect to present initial clinical data for both PRT543 and PRT811, our brain penetrant PRMT5 inhibitor, in the second half of the year. We continue to enroll the dose escalation portion of our Phase 1 trial of oral PRT1419, our MCL1 inhibitor, and plan to initiate dose expansion and combination cohorts in the second half of the year. Beyond our clinical pipeline, we remain focused on the advancement of our preclinical programs, and expect to submit an IND application for PRT2527, our CDK9 inhibitor, by year end. We are steadfast in our mission to develop novel therapeutic options for several cancers with high unmet need, and we look forward to providing updates on our continued progress as these programs mature."

ShowHide Related Items >><<
PRLD Prelude Therapeutics
$40.72 /

-0.66 (-1.59%)

PRLD Prelude Therapeutics
$40.72 /

-0.66 (-1.59%)

04/26/21 H.C. Wainwright
Prelude Therapeutics initiated with a Buy at H.C. Wainwright
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
PRLD Prelude Therapeutics
$40.72 /

-0.66 (-1.59%)

  • 07
    Jan
  • 25
    Sep
Over a quarter ago
Initiation
Prelude Therapeutics initiated with a Buy at H.C. Wainwright » 06:20
04/26/21
04/26
06:20
04/26/21
06:20
PRLD

Prelude Therapeutics

$34.74 /

-2.48 (-6.66%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns initiated coverage of Prelude Therapeutics with a Buy rating and $62 price target. Prelude constitutes a "differentiated proposition" within the arena of selective, targeted therapeutics for difficult-to-treat cancers, Burns tells investors in a research note.

ShowHide Related Items >><<
PRLD Prelude Therapeutics
$34.74 /

-2.48 (-6.66%)

PRLD Prelude Therapeutics
$34.74 /

-2.48 (-6.66%)

11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
10/20/20 Morgan Stanley
Prelude Therapeutics initiated with an Equal Weight at Morgan Stanley
PRLD Prelude Therapeutics
$34.74 /

-2.48 (-6.66%)

  • 07
    Jan
  • 25
    Sep
Conference/Events
Morgan Stanley to hold a virtual conference » 10:12
03/16/21
03/16
10:12
03/16/21
10:12
ALEC

Alector

$18.70 /

+0.05 (+0.27%)

, AVRO

Avrobio

$13.36 /

+0.34 (+2.61%)

, BOLT

Bolt Biotherapeutics

$39.81 /

+0.99 (+2.55%)

, CABA

Cabaletta Bio

$11.81 /

-0.01 (-0.08%)

, FHTX

Foghorn Therapeutics

$12.71 /

+0.1 (+0.79%)

, FULC

Fulcrum Therapeutics

$11.91 /

-0.06 (-0.50%)

, FUSN

Fusion Pharmaceuticals

$11.70 /

-0.05 (-0.43%)

, HAE

Haemonetics

$118.72 /

-0.44 (-0.37%)

, IMRA

Imara

$10.69 /

-0.08 (-0.74%)

, INSM

Insmed

$36.75 /

+0.15 (+0.41%)

, IVC

Invacare

$8.90 /

+0.13 (+1.48%)

, IRWD

Ironwood

$11.48 /

+0.36 (+3.24%)

, KPTI

Karyopharm

$12.60 /

+0.045 (+0.36%)

, KYMR

Kymera Therapeutics

$59.95 /

-0.335 (-0.56%)

, LEGN

Legend Biotech

$26.15 /

+0.2 (+0.77%)

, PRLD

Prelude Therapeutics

$60.50 /

+1.66 (+2.82%)

, RDUS

Radius Health

$23.11 /

-0.09 (-0.39%)

, RGNX

Regenxbio

$41.78 /

+0.06 (+0.14%)

, RPTX

Repare Therapeutics

$28.50 /

-0.05 (-0.18%)

, SGTX

Sigilon Therapeutics

$26.49 /

+0.36 (+1.38%)

, TNDM

TNDM

/

+

, ZNTL

Zentalis

$44.66 /

-1.09 (-2.38%)

Healthcare Corporate…

Healthcare Corporate Access Virtual Day to be held on March 16.

ShowHide Related Items >><<
ZNTL Zentalis
$44.66 /

-1.09 (-2.38%)

TNDM TNDM
/

+

SGTX Sigilon Therapeutics
$26.49 /

+0.36 (+1.38%)

RGNX Regenxbio
$41.78 /

+0.06 (+0.14%)

RDUS Radius Health
$23.11 /

-0.09 (-0.39%)

PRLD Prelude Therapeutics
$60.50 /

+1.66 (+2.82%)

LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

KYMR Kymera Therapeutics
$59.95 /

-0.335 (-0.56%)

KPTI Karyopharm
$12.60 /

+0.045 (+0.36%)

IVC Invacare
$8.90 /

+0.13 (+1.48%)

IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

INSM Insmed
$36.75 /

+0.15 (+0.41%)

IMRA Imara
$10.69 /

-0.08 (-0.74%)

HAE Haemonetics
$118.72 /

-0.44 (-0.37%)

FUSN Fusion Pharmaceuticals
$11.70 /

-0.05 (-0.43%)

FULC Fulcrum Therapeutics
$11.91 /

-0.06 (-0.50%)

FHTX Foghorn Therapeutics
$12.71 /

+0.1 (+0.79%)

CABA Cabaletta Bio
$11.81 /

-0.01 (-0.08%)

AVRO Avrobio
$13.36 /

+0.34 (+2.61%)

ALEC Alector
$18.70 /

+0.05 (+0.27%)

ALEC Alector
$18.70 /

+0.05 (+0.27%)

01/15/21 BofA
Alector reinstated with a Buy at BofA
11/11/20 Citi
Alector price target lowered to $31 from $40 at Citi
06/24/20 H.C. Wainwright
Alector initiated with a Buy at H.C. Wainwright
04/28/20 Goldman Sachs
Alector initiated with a Buy at Goldman Sachs
AVRO Avrobio
$13.36 /

+0.34 (+2.61%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
BOLT Bolt Biotherapeutics
$39.81 /

+0.99 (+2.55%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
03/02/21 Morgan Stanley
Bolt Biotherapeutics initiated with an Overweight at Morgan Stanley
03/02/21 Stifel
Bolt Biotherapeutics initiated with a Buy at Stifel
CABA Cabaletta Bio
$11.81 /

-0.01 (-0.08%)

01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
FHTX Foghorn Therapeutics
$12.71 /

+0.1 (+0.79%)

11/17/20 Morgan Stanley
Foghorn Therapeutics initiated with an Overweight at Morgan Stanley
11/17/20 Wedbush
Wedbush bullish on Foghorn Therapeutics, initiates with an Outperform
11/17/20 Wedbush
Foghorn Therapeutics initiated with an Outperform at Wedbush
11/17/20 Cowen
Foghorn Therapeutics initiated with an Outperform at Cowen
FULC Fulcrum Therapeutics
$11.91 /

-0.06 (-0.50%)

03/04/21 Piper Sandler
Fulcrum Therapeutics price target lowered to $20 from $22 at Piper Sandler
03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
FUSN Fusion Pharmaceuticals
$11.70 /

-0.05 (-0.43%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Morgan Stanley
Fusion Pharmaceuticals initiated with an Overweight at Morgan Stanley
07/21/20 Wedbush
Wedbush bullish on Fusion Pharmaceuticals, initiates with an Outperform
07/21/20 Jefferies
Fusion Pharmaceuticals initiated with a Buy at Jefferies
HAE Haemonetics
$118.72 /

-0.44 (-0.37%)

02/03/21 Barrington
Haemonetics upgraded to Outperform from Market Perform at Barrington
01/21/21 Barrington
Haemonetics downgraded to Market Perform from Outperform at Barrington
01/21/21 JMP Securities
Haemonetics price target raised to $140 from $110 at JMP Securities
11/05/20 Barrington
Haemonetics upgraded to Outperform from Market Perform at Barrington
IMRA Imara
$10.69 /

-0.08 (-0.74%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
INSM Insmed
$36.75 /

+0.15 (+0.41%)

02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
01/19/21 Credit Suisse
Insmed price target raised to $60 from $50 at Credit Suisse
12/17/20 Berenberg
Insmed initiated with a Buy at Berenberg
11/23/20 Evercore ISI
Insmed resumed with an Outperform at Evercore ISI
IVC Invacare
$8.90 /

+0.13 (+1.48%)

IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

02/09/21 Gordon Haskett
Ironwood odds of sale improved with CEO exit, says Gordon Haskett
11/06/20 Wells Fargo
Ironwood rally 'looks like a kneejerk overreaction,' says Wells Fargo
09/30/20
Fly Intel: Top five analyst downgrades
09/30/20 Wells Fargo
Ironwood downgraded to Equal Weight at Wells Fargo after pipeline miss
KPTI Karyopharm
$12.60 /

+0.045 (+0.36%)

02/12/21 Barclays
Karyopharm price target lowered to $22 from $26 at Barclays
02/01/21 Barclays
Karyopharm price target lowered to $26 from $31 at Barclays
12/11/20 RBC Capital
Karyopharm's NCCN inclusion should benefit uptake of Xpovio, says RBC Capital
09/25/20 RBC Capital
Karyopharm shares undervalued as seli moves into MF, says RBC Capital
KYMR Kymera Therapeutics
$59.95 /

-0.335 (-0.56%)

03/02/21 Piper Sandler
Kymera Therapeutics plans to file two INDs in 2H21, says Piper Sandler
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
12/04/20 H.C. Wainwright
Kymera Therapeutics initiated with a Buy at H.C. Wainwright
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

07/01/20 JPMorgan
Legend Biotech initiated with an Overweight at JPMorgan
07/01/20 Jefferies
Legend Biotech initiated with a Buy at Jefferies
06/30/20 Morgan Stanley
Legend Biotech initiated with an Overweight at Morgan Stanley
PRLD Prelude Therapeutics
$60.50 /

+1.66 (+2.82%)

11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
10/20/20 Morgan Stanley
Prelude Therapeutics initiated with an Equal Weight at Morgan Stanley
RDUS Radius Health
$23.11 /

-0.09 (-0.39%)

02/24/21 H.C. Wainwright
Radius Health price target raised to $25 from $22 at H.C. Wainwright
01/07/21 Citi
Radius Health price target raised to $30 from $25 at Citi
10/22/20 H.C. Wainwright
Radius Health price target lowered to $22 from $28 at H.C. Wainwright
09/29/20 JPMorgan
Radius Health resumed with a Neutral at JPMorgan
RGNX Regenxbio
$41.78 /

+0.06 (+0.14%)

02/09/21 Morgan Stanley
Sarepta denied motion to dismiss 'Wilson Wolf' case, says Morgan Stanley
01/20/21 RBC Capital
Regenxbio price target raised to $50 from $42 at RBC Capital
01/06/21 Chardan
Regenxbio named top 2021 pick with $100 target at Chardan
01/06/21 Raymond James
Regenxbio upgraded to Strong Buy from Outperform at Raymond James
RPTX Repare Therapeutics
$28.50 /

-0.05 (-0.18%)

03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
12/29/20 Northland
Northland ups Repare Therapeutics price target to $42, calls a Top Pick for 2021
10/28/20
Fly Intel: Top five analyst initiations
10/28/20 Northland
Repare Therapeutics initiated with an Outperform at Northland
SGTX Sigilon Therapeutics
$26.49 /

+0.36 (+1.38%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
TNDM TNDM
/

+

03/12/21 Piper Sandler
Tandem Diabetes competition concerns overblown, says Piper Sandler
02/25/21 Lake Street
Tandem Diabetes price target raised to $150 from $137 at Lake Street
02/04/21 Piper Sandler
Tandem trades at 'significant discount' to Insulet, says Piper Sandler
01/21/21 Citi
Citi adds Tandem, removes Guardant from 'Value Creators' list
ZNTL Zentalis
$44.66 /

-1.09 (-2.38%)

01/19/21 Wedbush
Zentalis initiated with an Outperform at Wedbush
09/28/20 Cantor Fitzgerald
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target
09/28/20 Cantor Fitzgerald
Zentalis initiated with an Overweight at Cantor Fitzgerald
08/27/20 H.C. Wainwright
Zentalis initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$44.66 /

-1.09 (-2.38%)

TNDM TNDM
/

+

RPTX Repare Therapeutics
$28.50 /

-0.05 (-0.18%)

RGNX Regenxbio
$41.78 /

+0.06 (+0.14%)

RDUS Radius Health
$23.11 /

-0.09 (-0.39%)

PRLD Prelude Therapeutics
$60.50 /

+1.66 (+2.82%)

LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

KYMR Kymera Therapeutics
$59.95 /

-0.335 (-0.56%)

KPTI Karyopharm
$12.60 /

+0.045 (+0.36%)

IVC Invacare
$8.90 /

+0.13 (+1.48%)

IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

INSM Insmed
$36.75 /

+0.15 (+0.41%)

IMRA Imara
$10.69 /

-0.08 (-0.74%)

HAE Haemonetics
$118.72 /

-0.44 (-0.37%)

FULC Fulcrum Therapeutics
$11.91 /

-0.06 (-0.50%)

FHTX Foghorn Therapeutics
$12.71 /

+0.1 (+0.79%)

CABA Cabaletta Bio
$11.81 /

-0.01 (-0.08%)

AVRO Avrobio
$13.36 /

+0.34 (+2.61%)

ALEC Alector
$18.70 /

+0.05 (+0.27%)

  • 05
    Feb
  • 20
    Jan
  • 08
    Jan
  • 07
    Jan
  • 04
    Dec
  • 20
    Nov
  • 23
    Oct
  • 25
    Sep
  • 21
    Aug
  • 30
    Jul
  • 15
    Jul
  • 26
    Jun
  • 19
    Jun
  • 05
    Jun
  • 05
    May
  • 03
    Apr
IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

SGTX Sigilon Therapeutics
$26.49 /

+0.36 (+1.38%)

RGNX Regenxbio
$41.78 /

+0.06 (+0.14%)

PRLD Prelude Therapeutics
$60.50 /

+1.66 (+2.82%)

LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

KPTI Karyopharm
$12.60 /

+0.045 (+0.36%)

IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

IMRA Imara
$10.69 /

-0.08 (-0.74%)

FHTX Foghorn Therapeutics
$12.71 /

+0.1 (+0.79%)

BOLT Bolt Biotherapeutics
$39.81 /

+0.99 (+2.55%)

AVRO Avrobio
$13.36 /

+0.34 (+2.61%)

LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

CABA Cabaletta Bio
$11.81 /

-0.01 (-0.08%)

Hot Stocks
Prelude Therapeutics expects cash to fund requirements into 2023 » 08:05
03/16/21
03/16
08:05
03/16/21
08:05
PRLD

Prelude Therapeutics

$58.84 /

+1.21 (+2.10%)

The Company believes that…

The Company believes that its current cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into 2023.

ShowHide Related Items >><<
PRLD Prelude Therapeutics
$58.84 /

+1.21 (+2.10%)

PRLD Prelude Therapeutics
$58.84 /

+1.21 (+2.10%)

11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
10/20/20 Morgan Stanley
Prelude Therapeutics initiated with an Equal Weight at Morgan Stanley
PRLD Prelude Therapeutics
$58.84 /

+1.21 (+2.10%)

  • 07
    Jan
  • 25
    Sep
PRLD Prelude Therapeutics
$58.84 /

+1.21 (+2.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.